These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33797782)

  • 21. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
    Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
    J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
    Mazarei G; Leavitt BR
    J Huntingtons Dis; 2015; 4(2):109-18. PubMed ID: 26397892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of LC-MS/MS methods for quantitative analysis of kynurenine pathway metabolites in human plasma and cerebrospinal fluid.
    Khetarpal V; Herbst T; Akhtar S; LaFayette A; Miller D; Farnham J; Steege T; Miao Z; Marks B; Ledvina A; Dominguez C
    Bioanalysis; 2023 Jun; 15(11):637-651. PubMed ID: 37170582
    [No Abstract]   [Full Text] [Related]  

  • 24. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.
    Shen H; Xu X; Bai Y; Wang X; Wu Y; Zhong J; Wu Q; Luo Y; Shang T; Shen R; Xi M; Sun H
    Eur J Med Chem; 2023 May; 251():115258. PubMed ID: 36917881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
    Havelund JF; Andersen AD; Binzer M; Blaabjerg M; Heegaard NHH; Stenager E; Faergeman NJ; Gramsbergen JB
    J Neurochem; 2017 Sep; 142(5):756-766. PubMed ID: 28628213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease.
    Heilman PL; Wang EW; Lewis MM; Krzyzanowski S; Capan CD; Burmeister AR; Du G; Escobar Galvis ML; Brundin P; Huang X; Brundin L
    Mov Disord; 2020 Nov; 35(11):2028-2037. PubMed ID: 32710594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain.
    Fuertig R; Ceci A; Camus SM; Bezard E; Luippold AH; Hengerer B
    Bioanalysis; 2016 Sep; 8(18):1903-17. PubMed ID: 27524289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.
    Vinther-Jensen T; Simonsen AH; Budtz-Jørgensen E; Hjermind LE; Nielsen JE
    Eur J Neurol; 2015 Oct; 22(10):1378-84. PubMed ID: 26073975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.
    Beal MF; Matson WR; Swartz KJ; Gamache PH; Bird ED
    J Neurochem; 1990 Oct; 55(4):1327-39. PubMed ID: 2144582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids.
    Yan J; Kothur K; Innes EA; Han VX; Jones HF; Patel S; Tsang E; Webster R; Gupta S; Troedson C; Menezes MP; Antony J; Ardern-Holmes S; Tantsis E; Mohammad S; Wienholt L; Pires AS; Heng B; Guillemin GJ; Guller A; Gill D; Bandodkar S; Dale RC
    EBioMedicine; 2022 Oct; 84():104280. PubMed ID: 36174397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
    Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease.
    Forrest CM; Mackay GM; Stoy N; Spiden SL; Taylor R; Stone TW; Darlington LG
    J Neurochem; 2010 Jan; 112(1):112-22. PubMed ID: 19845828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kynurenine and its metabolites in Alzheimer's disease patients.
    Gulaj E; Pawlak K; Bien B; Pawlak D
    Adv Med Sci; 2010; 55(2):204-11. PubMed ID: 20639188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid metabolites in tryptophan-kynurenine and nitric oxide pathways: biomarkers for acute neuroinflammation.
    Yan J; Kuzhiumparambil U; Bandodkar A; Bandodkar S; Dale RC; Fu S
    Dev Med Child Neurol; 2021 May; 63(5):552-559. PubMed ID: 33336374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
    Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
    Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot study.
    McGarry A; Gaughan J; Hackmyer C; Lovett J; Khadeer M; Shaikh H; Pradhan B; Ferraro TN; Wainer IW; Moaddel R
    Sci Rep; 2020 Nov; 10(1):20490. PubMed ID: 33235276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drosophila eye color mutants as therapeutic tools for Huntington disease.
    Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capillary electrochromatography-mass spectrometry of kynurenine pathway metabolites.
    Chawdhury ASMMR; Shamsi SA; Miller A; Liu A
    J Chromatogr A; 2021 Aug; 1651():462294. PubMed ID: 34098249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid levels of kynurenine pathway metabolites in patients with eating disorders: relation to clinical and biochemical variable.
    Demitrack MA; Heyes MP; Altemus M; Pigott TA; Gold PW
    Biol Psychiatry; 1995 Apr; 37(8):512-20. PubMed ID: 7542489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.